Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement for Boston Scientific...
Finance
Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
Guangzhou Baiyunshan Pharmaceutical Co., Ltd (SHA: 600332) announced its intention to acquire 100% equity of...
Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and...
Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
OTR Therapeutics Series-A Raises $100M for Neurology Pipeline
OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...
New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals
Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...
Humanwell Launches RMB250M Ruicheng Venture Fund for Health Tech
Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced the establishment of the Wuhan Ruicheng New...
Proviva’s PTX-912 PD-1 IL-2 Fusion Gets USD 30M Series A+ Boost
Proviva Therapeutics announced the completion of a Series A+ financing round, raising over USD 30 million led...
Phrontline Raises $60M Series Pre‑A+ to Advance Bispecific ADC Pipeline
Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD...
BrightGene Boosts Stake in Geek Gene to 12.8% with RMB 50 M Injection – Expanding Cell‑Therapy Portfolio
BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB 50 million (≈ US$7.2 million) capital increase...
Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact
Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...
Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake...
Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005
Brise Pharmaceuticals Co. Ltd., a Sherpa Healthcare Partners portfolio company, announced the successful close of...
DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform
Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...
Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal
Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...
Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development
China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....